Early pancreatic cancer detection

Overview

Información sobre este estudio

The primary purpose of this study is to standardize the collection of demographic, clinical, and imaging data, and biosamples for a large high-risk familial Pancreatic Ductal Adenocarinoma (PDAC) cohort at consortium clinical cancer centers, worldwide.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Individuals between 18 and 90 years of age.

Cohort 1 - Individuals without history of Pancreatic Ductal Adenocarcinoma (PDAC) meeting any of the following criteria:

  • 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤ 10 years younger than earliest PDAC in family at time of diagnosis.
  • 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family.
  • BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family.
  • Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+.
  • Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+.
  • Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+.

Cohort 2 - Individuals without history of PDAC meeting any of the following criteria:

  • ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+.
  • 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family.
  • 1 FDR with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member.

Cohort 3 - Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e., too young to qualify for Cohorts 1 or 2).

Cohort 4 - Individuals without history of PDAC presenting for evaluation who do not meet any criteria above after collection of full family history and/or germline testing.

Cohort 5 - Individuals who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g., blood, saliva, and/or buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4 and individuals with personal history of PDAC. 

Exclusion Criteria:

  • Individuals not meeting any single Inclusion Criteria.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Yan Bi, M.D., Ph.D.

Abierto para la inscripción

Contact information:

Yan Bi M.D., Ph.D.

(904) 953-6970

Bi.Yan@mayo.edu

More information

Publicaciones

Publications are currently not available

Información adicional de contacto

Formulario de contacto para ensayos sobre cáncer

Teléfono: 855-776-0015 (toll-free)

Preguntas de estudios clínicos para pacientes internacionales